Serum lysozyme, serum proteins, and immunoglobulin determinations in nonspecific inflammatory bowel disease

A sandwich FRET biosensor for lysozyme detection based on peptide-functionalized gold nanoparticles and FAM-labeled aptamer

Lysozyme (LYZ) plays a crucial role in the body's immune defense system. Monitoring LYZ levels can provide valuable insights into the diagnosis and severity assessment of various diseases. Traditionally, antibody-based sandwich assays are employed for LYZ detection, but they are often time-consuming and operationally complicated. In this research, a novel sandwich FRET biosensor was developed, which enables rapid detection of LYZ based on peptide-functionalized gold nanoparticles (pAuNPs) and FAM-labeled aptamer (Apt-FAM). Initially, a mixture of Apt-FAM and pAuNPs resulted in partial quenching of the Apt-FAM fluorescence emission through an inner filter effect (IFE), with negligible energy transfer because of the electrostatic repulsion between the negatively charged pAuNPs and Apt-FAM. The introduction of LYZ into the mixture drove the specific binding of Apt-FAM and pAuNPs to LYZ, facilitating the formation of a pAuNPs-LYZ-aptamer sandwich structure. The formation of this complex drew the pAuNPs and Apt-FAM into close enough proximity to enable FRET to occur, which in turn effectively quenched the fluorescence emission of FAM. The decrease in FAM fluorescence intensity was correlated with the increasing concentration of LYZ. Thus, a sandwich FRET biosensor was successfully developed for LYZ detection with a linear detection range of 0-1.75 μM and a detection limit of 85 nM. Additionally, the biosensor allowed visual detection of LYZ in a 96-well microplate, with a rapid response time of just 15 s. This study introduces a innovative sandwich FRET biosensor that combines aptamer and peptide recognition elements, offering a fast and antibody-free method for protein detection.

Application of functionalized silver nanoparticles as a biochemical sensor for selective detection of lysozyme protein in milk sample

Silver nanoparticles (AgNPs) functionalized with glutamic acid (GA) was used as a biochemical sensing probe in colorimetry for detection of lysozyme protein in milk samples. The method is based on the color change of AgNPs/GA from yellow to reddish-yellow differentiated with naked eyes for qualitative determination and red shift of localized surface plasmon resonance (LSPR) absorption signal intensity of AgNPs/GA in visible region used for quantitative determination of lysozyme. The control experiments were performed to demonstrate the electrostatic force of interactions between AgNPs/GA and protein molecule. A wide linear range of 3-150 nM with limit of detection of 1.5 nM was acquired for quantitative determination of lysozyme using AgNPs/GA as a biochemical sensing probe. The advantages of using AgNPs/GA as a biochemical sensing probe are simple, label-free and economic for determination of lysozyme from milk samples.

A magnetic nanoparticle-based aptasensor for selective and sensitive determination of lysozyme with strongly scattering silver nanoparticles

Qualitative and quantitative determination of lysozyme concentrations in urine and serum with high selectivity and sensitivity is important for diagnosing the progression of several diseases. In this report, we devised an improved method for specifically detecting lysozyme by combining magnetic nanoparticles (for separation and enrichment), an aptamer (for selective binding of lysozyme) and strongly scattering silver nanoparticles (AgNPs, for detection by light scattering, but also providing another level of selectivity due to their electrostatic binding with lysozyme). In this system, 0.4-30 nM lysozyme could be simply detected owing to the decreased light scattering of AgNPs in solution after magnetic separation, with a detection limit of 100 pM. In addition, lysozyme was also able to be semi-quantified by using the dark-field light scattering images of AgNPs after enrichment by the MNP-apt-lysozyme complex. Moreover, this design shows great promise for the robust and reliable detection of lysozyme in real samples, with a recovery rate ranging from 98.6% to 101.3% in human serum samples. Therefore, this assay provided robust measurements with good specificity, sensitivity, and tolerance of changes in the sample matrix. We expect that this MNP-based aptasensor may find utility in the accurate diagnosis of lysozyme-related diseases.

Core-shell Cu@Au nanoparticles-based colorimetric aptasensor for the determination of lysozyme

A growing body of evidence indicates that lysozyme plays a significant role as an indicator for many diseases and a drug for treatment of infections, ulcers and to study the spatial conformation, enzyme kinetics, and molecular immunology. Therefore, highly sensitive determination of lysozyme is necessary and vital in a wide variety of fields. In this work, we put forward a simple but effective strategy for colorimetric visualization of lysozyme based on iodide-responsive Cu@Au nanoparticles (Cu@Au NPs) as well as the iodide-catalyzed H₂O₂-TMB (3,3,5,5-tetramethylbenzidine) reaction system. Colorimetric detection is applied because of its simplicity, fast response for analysis, high detection limit, low costs and practicality. In our strategy, iodide is applied for the reason that it can induce an obvious color change of the Cu@Au nanoparticles solution from gray to red, along with the change of morphologies of the Cu@Au nanoparticles from irregular to spherical. Consequently, this phenomenon results in colorimetric signal variation of the iodide-catalytic H₂O₂-TMB system. What's more, by quite simple biomolecule modification on the Cu@Au nanoparticles surface, an all-purpose colorimetric platform is established for the accurate detection of lysozyme, which could lead to the change of Cu@Au NP concentration through molecular recognition. The results show that modified Cu-Au NPs successfully achieved a simple, selective, visualized, and ultrasensitive detection of lysozyme with a linear range from 10^-7 to 10^-3M and a detection limit of 60nM.

Turn-off–on fluorescence probe based on 3-mercaptopropionic acid-capped CdS quantum dots for selective and sensitive lysozyme detection

The fluorescence of CdS QDs was first quenched by hemoglobin and then restored with the increasing concentration of the lysozyme in a certain range. Therefore, a fluorescence assay for the determination of lysozyme was established.

Influence of the charge of low molecular weight proteins on their efficacy of filtration and/or adsorption on dialysis membranes with different intrinsic properties

Hemodialysis membranes eliminate by filtration low-molecular-weight toxic metabolites (urea and creatinine) with minimum interactions between blood components and the membrane itself. However, the ability of a membrane to adsorb specific proteins could be beneficial if the accumulation of these same proteins is implicated in the genesis of a pathological condition. Beta-amyloidosis which accompanies the elevation of beta2-microglobulin (11.8 kDa) in the plasma of dialysed patients is one such condition (Biochem. Biophys. Res. Commun. 129 (3) (1985) 701-706: Lancet 1 (1986) 1240-1311). To determine whether increases in plasma beta2-microglobulin levels were due to differences in filtration efficacy of the membrane used and/or to certain characteristics of this protein, e.g. its charge (pI 5.7) the adsorption and filtration of [3H] beta2-microglobulin and [3H] lysozyme of similar MW 14.5 kDa, but pI: 10.8 were compared on different membranes. It was found that, neither [3H] beta2-microglobulin nor [3H] lysozyme are removed by cuprophan, whereas over 75% of beta2-microglobulin is removed by filtration on polyacrylonitrile, polyacrylonitrile-polyethyleneimine, polysulfone and >95% by adsorption to polymethylmethacrylate-BK. For lysozyme, removal by adsorption is >95% on polyacrylonitrile and polyacrylonitrile-polyethyleneimine, 72% on polymethylmethacrylate-BK and by filtration is 95% on polysulfone. Hemodialysis membranes must therefore not simply be considered as filters of low-molecular-weight metabolites but should be equally assessed for their capacity to eliminate potentially deleterious low-molecular-weight plasma proteins.

The effect of high-dose methotrexate on renal tubules as indicated by urinary lysozyme concentration

Lysozyme was measured after 186 doses of methotrexate (MTX) to 88 patients. After 7.5% of the doses, lysozyme rose to between 2 and 19 micrograms/cc and in 3.2% it rose to between 20 and 120 micrograms/cc. These increases had no relationship to the age of the patients, their dose of MTX, the total number of times that MTX had been given, nor to rises in serum creatinine. It did correlate with the administration of aminoglycosides (a part of the supportive care of these patients) in two thirds of these cases. In patients who did not receive aminoglycosides, no urinary lysozyme concentration rose above 19 micrograms/cc, not even in the patients who became oliguric or required hemoperfusion. Most of these rises occurred early and were of 24 to 48 hour duration. The rises occurring after five days were persistent and were associated with prolonged MTX serum concentrations, suggesting that tubular damage due to MTX was the result of prolonged exposure to MTX, rather than the primary cause of kidney damage, i.e., the event causing the prolonged serum concentrations.

Lysozyme in chronic liver disease: a biochemical and histological study

Serum lysozyme activities and semiquantitative analysis of tissue lysozyme distribution were studied in patients with primary biliary cirrhosis (PBC), chronic hepatitis (CH), miscellaneous liver diseases, and normal subjects. Serum lysozyme was significantly raised in PBC and CH. Portal venous blood has similar lysozyme activities to peripheral venous blood in a group of various liver diseases. Lysozyme-containing intralobular cells were decreased in all liver diseases studied but portal tract lysozyme was increased only in PBC and CH. Thus the increase in serum lysozyme in PBC and CH appears to originate from the portal inflammatory infiltrate, seen in these diseases.